3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Stomach Neoplasms
7
Rectal Neoplasms
5
Nasopharyngeal Carcinoma
5
Colorectal Neoplasms
5
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Pancreatic Neoplasms
3
Melanoma
3
Esophageal Squamous Cell Carcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Advanced Solid Tumor
2
Triple Negative Breast Neoplasms
1
Squamous Cell Non-small Cell Lung Cancer
1
Solid Tumor, Adult
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms by Site
1
Interventions
pembrolizumab
4
Doxorubicin
3
Specimen Handling
2
spartalizumab
1
regorafenib
1
peposertib
1
liposomal doxorubicin
1
cabozantinib
1
X-Rays
1
Standard of Care
1
Quality of Life
1
Propranolol
1
Magnetic Resonance Spectroscopy
1
Injections
1
Ifosfamide
1
Histamine H2 Antagonists
1
Famotidine
1
Dactinomycin
1
Biopsy
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Histiocytoma, Malignant Fibrous
×
spartalizumab
×
Clear all
NCT05961761
2023-07-27
PROPANE
Herlev and Gentofte Hospital
Phase 2
Recruiting
80 enrolled